Efficacy of Telmisartan Plus Amlodipine in Nonresponders to CCB Monotherapy

<table class="table-group" width="800px"><tr class="fig-image" id="a"><td><img alt="627938.fig.003a" src="https://static-preview.hindawi.com/articles/ijhy/volume-2013/627938/figures/627938.fig.003a.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(a) </b>Patients not at goal with A5 monotherapy </td></tr></table></td></tr><tr class="fig-image" id="b"><td><img alt="627938.fig.003b" src="https://static-preview.hindawi.com/articles/ijhy/volume-2013/627938/figures/627938.fig.003b.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(b) </b>Patients not at goal with A10 monotherapy </td></tr></table></td></tr></table>

<table>BP goal attainment rates at week 8. A5: amlodipine 5 mg; A10: amlodipine 10 mg; BP: blood pressure; DBP: diastolic blood pressure; SBP: systolic blood pressure; T40: telmisartan 40 mg; T80: telmisartan 80 mg.</table>

International Journal of Hypertension

fig3

Figure 3

Figure 3: Efficacy of Telmisartan Plus Amlodipine in Nonresponders to CCB Monotherapy 